Why Arcturus Therapeutics Stock Is Plunging Today
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021.
Investors had high hopes that a single dose of ARCT-021 could be highly effective at preventing infection by the coronavirus that causes COVID-19. But Arcturus' latest results poured cold water on those expectations.
Image source: Getty Images.
Source Fool.com